Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects.
Maniscalco GT, Ferrara AL, Liotti A, Manzo V, Di Battista ME, Salvatore S, Graziano D, Viola A, Amato G, Moreggia O, Di Giulio Cesare D, Alfieri G, Di Iorio W, Della Rocca G, Andreone V, De Rosa V. Maniscalco GT, et al. Among authors: di giulio cesare d. Mult Scler Relat Disord. 2022 Jun;62:103800. doi: 10.1016/j.msard.2022.103800. Epub 2022 Apr 12. Mult Scler Relat Disord. 2022. PMID: 35462168 Free PMC article.
Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
Maniscalco GT, Manzo V, Ferrara AL, Perrella A, Di Battista M, Salvatore S, Graziano D, Viola A, Amato G, Moreggia O, Di Giulio Cesare D, Barbato S, Servillo G, Longo K, Di Giovanni M, Scarpati B, Muggianu SM, Longo G, Russo G, Andreone V, De Rosa V. Maniscalco GT, et al. Among authors: di giulio cesare d. Mult Scler Relat Disord. 2022 Feb;58:103455. doi: 10.1016/j.msard.2021.103455. Epub 2021 Dec 18. Mult Scler Relat Disord. 2022. PMID: 34929455 Free PMC article.
The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study.
Maniscalco GT, Scavone C, Mascolo A, Manzo V, Prestipino E, Guglielmi G, Aiezza ML, Cozzolino S, Bracco A, Moreggia O, Di Giulio Cesare D, Ziello AR, Falco A, Massa M, Majolo M, Raiola E, Soprano R, Russo G, Longo G, Andreone V, Capuano A. Maniscalco GT, et al. Among authors: di giulio cesare d. J Clin Med. 2022 Nov 21;11(22):6855. doi: 10.3390/jcm11226855. J Clin Med. 2022. PMID: 36431332 Free PMC article.
Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Maniscalco GT, Liotti A, Ferrara AL, Prestipino E, Salvatore S, Di Battista ME, Moreggia O, Di Giulio Cesare D, Vastano R, Belardo M, Napolitano M, Ranieri A, Longo K, Andreone V, De Rosa V. Maniscalco GT, et al. Among authors: di giulio cesare d. Mult Scler Relat Disord. 2022 Dec;68:104371. doi: 10.1016/j.msard.2022.104371. Epub 2022 Oct 23. Mult Scler Relat Disord. 2022. PMID: 36544318 Free PMC article.
Three Doses of COVID-19 Vaccines: A Retrospective Study Evaluating the Safety and the Immune Response in Patients with Multiple Sclerosis.
Maniscalco GT, Di Giulio Cesare D, Liguori V, Manzo V, Prestipino E, Salvatore S, Di Battista ME, Moreggia O, Ziello AR, Andreone V, Scavone C, Capuano A. Maniscalco GT, et al. Among authors: di giulio cesare d. J Clin Med. 2023 Jun 23;12(13):4236. doi: 10.3390/jcm12134236. J Clin Med. 2023. PMID: 37445269 Free PMC article.